SPRBSpruce Biosciences Inc
SPRB
Spruce Biosciences Inc5,040
Mkt Cap
$62.34MVolume
260,933.0052W High
$240.0052W Low
$4.28PE Ratio
-0.69SPRB Fundamentals
Price
$53.48Prev Close
$58.25Open
$60.7650D MA
$80.29Beta
1.05Avg. Volume
29,516.10EPS (Annual)
-$96.39P/B
6.09Rev/Employee
$233,857.14$18.66
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy
Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings.
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·12h ago
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·1d ago
Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapys Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·13d ago
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Rating of "Hold" from Brokerages
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been given a consensus recommendation of "Hold" by the nine brokerages that are presently covering the stock, MarketBeat.com...
MarketBeat·13d ago
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·15d ago
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences
Harbour BioMed exercises its warrant to buy Spruce Biosciences shares, raising its stake to about 3.8% as the companies work together on the SPR202 drug program.read more...
Benzinga·28d ago
Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences
(RTTNews) - Harbour BioMed announced that, through its wholly-owned subsidiary, it has exercised its warrant to acquire common stock in Spruce Biosciences Inc. (SPRB). As a result of this...
Nasdaq News: Markets·1mo ago
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration PR Newswire...
PR Newswire·1mo ago
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet...
Business Wire·1mo ago
<
1
2
...
>